MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Spyre Therapeutics, Inc. (NASDAQ: SYRE), formerly, Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)*
Organization & Developments: Aeglea
Parents
Spyre Therapeutics, Inc. (NASDAQ: SYRE), formerly, Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)*
Children
*Austin biotech company is partnering with University of Texas researcher George Georgiou on a way to administer the treatment intravenously to increase its effectiveness.
*Research into engineer enzymes that degrade amino acids present in cancerous tumors.
*Research into novel enzymes that degrade naturally occurring amino acids, which tumors need to survive.
2019: Aeglea Biotherapeutics Has Potential In Rare Diseases; We Remain Neutral - Aeglea BioTherapeutics (NASDAQ:AGLE)
2020: Aeglea BioTherapeutics: Human Enzyme-Based Platform Tackles Multiple Rare Diseases
2022: Aeglea culls workers, shifts pipeline focus after knockback by FDA
2024: Spyre Therapeutics: Different Name, Same Tune
2025: Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight
2025: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2025: Spyre Therapeutics: Targeting The Future Of IBD Treatment
2025: Spyre Therapeutics: Targeting The Future Of IBD Treatment_ seekingalpha.com
2026: Spyre Therapeutics inflammatory bowel disease drug shows promise in trial
Jumps
*Key People: Aeglea
Finance & Acquisitions: Aeglea